Monopar Therapeutics Inc.: 10-Q filed 2018-05-11

Name: Monopar Therapeutics Inc.: 10-Q filed 2018-05-11
Creator: Monopar Therapeutics Inc.

What Monopar Therapeutics Inc. reported in its quarterly report filed 2018-05-11 (fiscal Q1 2018): 19 published measures, 40 facts as tagged in accession 0001654954-18-005108.

This filing

Form: 10-Q (quarterly report)
Filed: 2018-05-11
Fiscal period: fiscal Q1 2018
Accession: 0001654954-18-005108 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Monopar Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2018-03-31	9,148,176	USD
At 2017-12-31	9,931,267	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2018-03-31	290,597	USD
At 2017-12-31	311,867	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2018-03-31	8,857,579	USD
At 2017-12-31	9,619,400	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2018-03-31	8,173,045	USD
At 2017-12-31	8,981,894	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	-876,347	USD	90
2017-01-01 to 2017-03-31	-372,915	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	-808,849	USD	90
2017-01-01 to 2017-03-31	-311,486	USD	90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	0	USD	90
2017-01-01 to 2017-03-31	0	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	0	USD	90
2017-01-01 to 2017-03-31	990,002	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2018-03-31	-19,304,127	USD
At 2017-12-31	-18,427,780	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	-897,260	USD	90
2017-01-01 to 2017-03-31	-373,839	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2018-03-31	8,348,145	USD
At 2017-12-31	9,131,236	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2018-03-31	290,597	USD
At 2017-12-31	311,867	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	897,260	USD	90
2017-01-01 to 2017-03-31	373,839	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	457,141	USD	90
2017-01-01 to 2017-03-31	133,736	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2018-03-31	9,291,421	shares
At 2017-12-31	9,291,421	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2018-03-31	8,973,076	USD
At 2017-12-31	9,781,925	USD
At 2017-03-31	3,551,520	USD
At 2016-12-31	2,873,004	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2018-03-31	28,152,415	USD
At 2017-12-31	28,037,889	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	440,119	USD	90
2017-01-01 to 2017-03-31	240,103	USD	90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	0	USD	90
2017-01-01 to 2017-03-31	990,002	USD	90

Inspect the source

Entity: Monopar Therapeutics Inc. / CIK 0001645469
Captured: 2026-09-21T17:22:36.466Z
SEC response SHA-256: 11b3f240217511123d89b32408ab3beb4dce0c8844d2a4f4fb7c1085084888d1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001645469.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))